Source: Annual Congress 2009 - Functional insights into COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Shrikrishna, P. Albert, P. M. Calverley, M. I. Polkey, J. Seymour, M. A. Spruit, R. Tal-Singer, E. F. M. Wouters (London, Liverpool, United Kingdom; Horn, Maastricht, Netherlands; Philadelphia, United States Of America). Quadriceps weakness in GOLD stage II COPD: data from the ECLIPSE study. Eur Respir J 2009; 34: Suppl. 53, 3811

Member's Comments

No comment yet.

Related content which might interest you: Ultrasound measurement of quadriceps wasting in patients with GOLD stage II COPD and its relationship to physical activity Source: Annual Congress 2011 - Innovative methods in clinical physiology Year: 2011 Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort Source: Eur Respir J 2013; 42: 636-646 Year: 2013 Effects of respiratory muscle training and cycle ergometry training in patients with severe COPD (GOLD IV) Source: Eur Respir J 2004; 24: Suppl. 48, 517s Year: 2004 Rehabilitation programs in patients in different severity stage of COPD (GOLD II-to-IV): analysis of the results Source: Eur Respir J 2005; 26: Suppl. 49, 69s Year: 2005 Effects of tiotropium on lung volumes during exercise in GOLD stage II to IV COPD patients Source: Eur Respir J 2006; 28: Suppl. 50, 171s Year: 2006 Estimation of a disease progression model for COPD using data from the ECLIPSE study Source: Annual Congress 2013 –Health economics of airway diseases Year: 2013 Validation of non-spirometric predictors of COPD to the GOLD stage classification Source: Eur Respir J 2002; 20: Suppl. 38, 123s Year: 2002 Prediction of muscle weakness in COPD: results from modelling using the ERICA cohort Source: International Congress 2019 – Pulmonary rehabilitation for obstructive lung diseases Year: 2019 Physician-diagnosed COPD GOLD stage IV in Östersund, Sweden: prevalence and patient characteristics Source: Eur Respir J 2006; 28: Suppl. 50, 447s Year: 2006 COPD GOLD stage 1: Is it really a disease? Source: Annual Congress 2011 - COPD mechanisms Year: 2011 The prevalence of QTc-prolongation increase by GOLD stage in COPD Source: International Congress 2017 – Prevalence, prognosis and comorbidities of COPD and factors associated with lung function Year: 2017 Hyperinflation in GOLD 2 COPD Source: Eur Respir J 2006; 28: Suppl. 50, 806s Year: 2006 The quadriceps isometric strength evaluation: a possible outcome index in II and III G.O.L.D. COPD patients Source: Eur Respir J 2003; 22: Suppl. 45, 550s Year: 2003 Survival in three years of COPD patients according to GOLD 2003 and GOLD 2014 Source: International Congress 2015 – Latest insights into the management of chronic respiratory diseases Year: 2015 A comparison of COPD patients with and without ACOS in the ECLIPSE study Source: Eur Respir J 2016; 47:1559-1562 Year: 2016 Is GOLD stage 0 a good predictor of the development of COPD? Preliminary results from the ECRHS II Source: Eur Respir J 2005; 26: Suppl. 49, 434s Year: 2005 Peak inspiratory flow evaluation in different stages’ COPD patients using in-check method (INSPIRE STUDY) Source: International Congress 2016 – Targeting care, pulmonary rehabilitation, management, and self-management of COPD exacerbations in primary care Year: 2016 Discovery of novel disease-related biomarkers for GOLD stage II COPD: A prospective exploratory clinical study Source: Annual Congress 2010 - Novel mechanisms in COPD Year: 2010 GOLD stage 0 and risk of COPD Source: Eur Respir J 2003; 22: Suppl. 45, 352s Year: 2003 Efficacy of revefenacin based on GOLD 2017 categories: reanalysis of phase 3 data in patients with COPD Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019